Marie Elebring

440 total citations
13 papers, 255 citations indexed

About

Marie Elebring is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Marie Elebring has authored 13 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pharmacology. Recurrent topics in Marie Elebring's work include DNA and Nucleic Acid Chemistry (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Marie Elebring is often cited by papers focused on DNA and Nucleic Acid Chemistry (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Marie Elebring collaborates with scholars based in Sweden, United Kingdom and Finland. Marie Elebring's co-authors include Lars Weidolf, Shalini Andersson, Madeleine Antonsson, Rasmus Jansson‐Löfmark, Margareta Behrendt, Jason L. Johnson, Regina Fritsche‐Danielson, Craig R. Jackson, William L. McPheat and Håkan Wennbo and has published in prestigious journals such as Circulation, European Heart Journal and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Marie Elebring

11 papers receiving 248 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marie Elebring Sweden	10	139	49	48	37	27	13	255
Anees M. Dauki United States	8	99 0.7×	40 0.8×	53 1.1×	35 0.9×	64 2.4×	15	258
Cui-Hong Zhu China	10	111 0.8×	49 1.0×	94 2.0×	56 1.5×	23 0.9×	13	302
Klemens Lustig Germany	11	152 1.1×	38 0.8×	49 1.0×	17 0.5×	59 2.2×	14	303
Dean Messing United States	10	139 1.0×	41 0.8×	55 1.1×	28 0.8×	17 0.6×	14	281
Mandeep Takhar Canada	9	159 1.1×	45 0.9×	48 1.0×	14 0.4×	42 1.6×	13	320
Yuhong Yao China	8	193 1.4×	67 1.4×	84 1.8×	18 0.5×	48 1.8×	13	307
Marwa Kamel Egypt	12	137 1.0×	65 1.3×	64 1.3×	17 0.5×	19 0.7×	21	384
Laura Lopez‐Sanz Spain	12	155 1.1×	24 0.5×	94 2.0×	21 0.6×	35 1.3×	20	344
Wenjuan Mei China	14	257 1.8×	103 2.1×	81 1.7×	16 0.4×	33 1.2×	35	466
Denise M. Wilcox United States	6	128 0.9×	22 0.4×	36 0.8×	19 0.5×	15 0.6×	8	338

Countries citing papers authored by Marie Elebring

Since Specialization

Citations

This map shows the geographic impact of Marie Elebring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie Elebring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie Elebring more than expected).

Fields of papers citing papers by Marie Elebring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie Elebring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie Elebring. The network helps show where Marie Elebring may publish in the future.

Co-authorship network of co-authors of Marie Elebring

This figure shows the co-authorship network connecting the top 25 collaborators of Marie Elebring. A scholar is included among the top collaborators of Marie Elebring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie Elebring. Marie Elebring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Elebring, Marie, et al.. (2025). AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies. European Heart Journal. 46(Supplement_1).

Gennemark, Peter, Nigel Davies, Marie Elebring, et al.. (2023). Injectable Biodegradable Silica Depot for Controlled Subcutaneous Delivery of Antisense Oligonucleotides with beyond Monthly Administration. Molecular Pharmaceutics. 21(1). 143–151.

Huang, Yingbo, Weifeng Tang, Anna Lundahl, et al.. (2023). Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. 114(4). 825–835. 9 indexed citations

Li, Xueqing, Marie Elebring, Anders Dahlén, & Lars Weidolf. (2023). In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Chromatography High-Resolution Mass Spectrometry: A Cross-Species Comparison in Animals and Humans. Drug Metabolism and Disposition. 51(10). 1350–1361. 10 indexed citations

Weidolf, Lars, Anders Björkbom, Anders Dahlén, et al.. (2021). Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates. Drug Discovery Today. 26(10). 2244–2258. 20 indexed citations

PEHRSSON, S. KENNETH, Bengt Kull, Marie Elebring, et al.. (2019). Abstract 11146: AZD3366-an Optimized Recombinant Human Apyrase Combining Anti Platelet, Anti Inflammatory and Tissue Protective Actions With Low Bleeding Risk for Potential Mitigation of Thromboembolic Complications. Circulation. 1 indexed citations

Andersson, Shalini, Madeleine Antonsson, Marie Elebring, Rasmus Jansson‐Löfmark, & Lars Weidolf. (2018). Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. Drug Discovery Today. 23(10). 1733–1745. 46 indexed citations

Johansson, Susanne, et al.. (2017). Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions. Clinical Pharmacology in Drug Development. 6(5). 466–475. 10 indexed citations

Kenna, J. Gerry, Simone H. Stahl, Alison J. Foster, et al.. (2014). Multiple Compound-Related Adverse Properties Contribute to Liver Injury Caused by Endothelin Receptor Antagonists. Journal of Pharmacology and Experimental Therapeutics. 352(2). 281–290. 35 indexed citations

10.

Hellmold, Heike, Hui Zhang, Jan Andersson, et al.. (2007). Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats. Toxicological Sciences. 98(1). 63–74. 28 indexed citations

11.

Johnson, Jason L., Regina Fritsche‐Danielson, Margareta Behrendt, et al.. (2006). Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovascular Research. 71(3). 586–595. 61 indexed citations

12.

Ericsson, Hans, Bengt Hamrén, Sara Bergstrand, et al.. (2004). Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.. PubMed. 32(9). 923–9. 23 indexed citations

13.

Ericsson, Hans, Bengt Hamrén, Sara Bergstrand, et al.. (2004). PHARMACOKINETICS AND METABOLISM OF TESAGLITAZAR, A NOVEL DUAL-ACTING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α/γ AGONIST, AFTER A SINGLE ORAL AND INTRAVENOUS DOSE IN HUMANS. Drug Metabolism and Disposition. 32(9). 923–929. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact